<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01725009</url>
  </required_header>
  <id_info>
    <org_study_id>EP0038</org_study_id>
    <nct_id>NCT01725009</nct_id>
  </id_info>
  <brief_title>Multiple-dose Study of Levetiracetam Injection in Japanese and Caucasian Healthy Males</brief_title>
  <official_title>A Single-center, Open-label, Multiple-dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Levetiracetam Administered as Intravenous Infusion in Japanese and Caucasian Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UCB Japan Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UCB Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the pharmacokinetics of levetiracetam following single and multiple 15-minute
      intravenous infusions of 1500 mg levetiracetam between Japanese and Caucasian healthy male
      subjects
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum plasma concentration after a single dose (Cmax)</measure>
    <time_frame>Multiple samples at predose, 5, 10, 15, 30, 45 minutes, 1, 1.5, 2, 3, 6, 9, 12, 24 and 36 hours after the start of Intravenous (IV) infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the curve from zero to the time of the last quantifiable concentration after a single (AUC(0-t))</measure>
    <time_frame>Multiple samples at predose, 5, 10, 15, 30, 45 minutes, 1, 1.5, 2, 3, 6, 9, 12, 24 and 36 hours after the start of IV infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration time curve from zero to infinity after a single dose (AUC)</measure>
    <time_frame>Multiple samples at predose, 5, 10, 15, 30, 45 minutes, 1, 1.5, 2, 3, 6, 9, 12, 24 and 36 hours after the start of IV infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Body-weight normalized maximum plasma concentration after a single dose (Cmax)</measure>
    <time_frame>Multiple samples at predose, 5, 10, 15, 30, 45 minutes, 1, 1.5, 2, 3, 6, 9, 12, 24 and 36 hours after the start of IV infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Body-weight normalized area under the curve from zero to the time of the last quantifiable concentration after a single, (AUC(0-t))</measure>
    <time_frame>Multiple samples at predose, 5, 10, 15, 30, 45 minutes, 1, 1.5, 2, 3, 6, 9, 12, 24 and 36 hours after the start of IV infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Body weight normalized area under the plasma concentration time curve from zero to infinity after a single dose, (AUC)</measure>
    <time_frame>Multiple samples at predose, 5, 10, 15, 30, 45 minutes, 1, 1.5, 2, 3, 6, 9, 12, 24 and 36 hours after the start of IV infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum plasma concentration at steady state after multiple doses (Cmax,ss)</measure>
    <time_frame>Multiple samples at predose, 5, 10, 15, 30, 45 minutes, 1, 1.5, 2, 3, 6, 9 and 12 hours after the start of IV infusion.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the curve over a dosing interval at steady state after multiple doses (AUCτss)</measure>
    <time_frame>Multiple samples at predose, 5, 10, 15, 30, 45 minutes, 1, 1.5, 2, 3, 6, 9 and 12 hours after the start of IV infusion.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Body-weight normalized maximum plasma concentration at steady state after multiple doses (Cmax,ss)</measure>
    <time_frame>Multiple samples at predose, 5, 10, 15, 30, 45 minutes, 1, 1.5, 2, 3, 6, 9 and 12 hours after the start of IV infusion.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Body-weight normalized area under the curve over a dosing interval at steady state after multiple doses (AUCτss)</measure>
    <time_frame>Multiple samples at predose, 5, 10, 15, 30, 45 minutes, 1, 1.5, 2, 3, 6, 9 and 12 hours after the start of IV infusion.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the curve over a dosing interval, (AUCτ (τ = 12 hours))</measure>
    <time_frame>Multiple samples at predose, 5, 10, 15, 30, 45 minutes, 1, 1.5, 2, 3, 6, 9 and 12 hours after the start of IV infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum plasma concentration after a single dose (tmax)</measure>
    <time_frame>Multiple samples at predose, 5, 10, 15, 30, 45 minutes, 1, 1.5, 2, 3, 6, 9, 12, 24 and 36 hours after the start of IV infusion.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal elimination half-life after a single dose (t1/2)</measure>
    <time_frame>Multiple samples at predose, 5, 10, 15, 30, 45 minutes, 1, 1.5, 2, 3, 6, 9, 12, 24 and 36 hours after the start of IV infusion.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>First order terminal elimination rate constant after a single dose (λz)</measure>
    <time_frame>Multiple samples at predose, 5, 10, 15, 30, 45 minutes, 1, 1.5, 2, 3, 6, 9, 12, 24 and 36 hours after the start of IV infusion.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total body clearance after a single dose (CL)</measure>
    <time_frame>Multiple samples at predose, 5, 10, 15, 30, 45 minutes, 1, 1.5, 2, 3, 6, 9, 12, 24 and 36 hours after the start of IV infusion.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution during terminal phase after a single dose (Vz)</measure>
    <time_frame>Multiple samples at predose, 5, 10, 15, 30, 45 minutes, 1, 1.5, 2, 3, 6, 9, 12, 24 and 36 hours after the start of IV infusion.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean residence time after a single dose (MRT)</measure>
    <time_frame>Multiple samples at predose, 5, 10, 15, 30, 45 minutes, 1, 1.5, 2, 3, 6, 9, 12, 24 and 36 hours after the start of IV infusion.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum plasma concentration at steady state after multiple doses (tmax,ss)</measure>
    <time_frame>Multiple samples at predose, 5, 10, 15, 30, 45 minutes, 1, 1.5, 2, 3, 6, 9 and 12 hours after the start of IV infusion.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total body clearance at steady state after multiple doses (CLss)</measure>
    <time_frame>Multiple samples at predose, 5, 10, 15, 30, 45 minutes, 1, 1.5, 2, 3, 6, 9 and 12 hours after the start of IV infusion.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Linearity factor after multiple doses (LF)</measure>
    <time_frame>Multiple samples at predose, 5, 10, 15, 30, 45 minutes, 1, 1.5, 2, 3, 6, 9, 12, 24 and 36 hours after the start of the first IV infusion and at predose, 5, 10, 15, 30, 45 minutes, 1, 1.5, 2, 3, 6, 9 and 12 hours after the start of the last IV infusion.</time_frame>
    <description>LF = AUCτss / AUC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation ratio (RAUC) after multiple doses</measure>
    <time_frame>Multiple samples at predose, 5, 10, 15, 30, 45 minutes, 1, 1.5, 2, 3, 6, 9 and 12 hours after the start of the first and the last IV infusions</time_frame>
    <description>RAUC = AUCτss / AUCτ</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Levetiracetam IV infusions in Japanese</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple 15-minute intravenous infusions of 1500 mg levetiracetam in Japanese subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Levetiracetam IV infusions in Caucasian</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple 15-minute intravenous infusions of 1500 mg levetiracetam in Caucasian subjects</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Multiple 15-minute intravenous infusions of 1500 mg levetiracetam</intervention_name>
    <description>Strength, 100 mg/mL; Form, concentrate for solution for infusion; Frequency, twice a day; Duration, 7 days</description>
    <arm_group_label>Levetiracetam IV infusions in Japanese</arm_group_label>
    <arm_group_label>Levetiracetam IV infusions in Caucasian</arm_group_label>
    <other_name>E-Keppra</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy Japanese and Caucasian males with the age between 20 and 40 years old,

          -  with the body mass index between 20 and 25,

          -  with the body weight between 60 and 80kg

        Exclusion Criteria:

          -  subjects who have a history or presence of drug addiction or excessive use of alcohol

          -  current smokers and former smokers who have given up since less than 6 months before
             the first dose

          -  heavy caffeine drinker
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>01</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 7, 2012</study_first_submitted>
  <study_first_submitted_qc>November 9, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 12, 2012</study_first_posted>
  <last_update_submitted>March 27, 2013</last_update_submitted>
  <last_update_submitted_qc>March 27, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 29, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy volunteers</keyword>
  <keyword>Japanese</keyword>
  <keyword>Caucasian</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etiracetam</mesh_term>
    <mesh_term>Piracetam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

